Astellas, the drug’s manufacturer, said in a statement that patient safety is its top priority. “It’s important to note that the overall benefit-risk of Veozah has not changed and remains ...

WEDNESDAY, Dec. 18, 2024 (HealthDay News) -- The U.S. Food and Drug Administration (FDA) has issued its most serious warning -- a black-box warning -- for Veozah, a medication used to relieve hot ...

Veozah was approved in 2023. It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B, which plays a role in the brain’s regulation of body temperature.

Veozah was approved in 2023. It works without hormones to reduce hot flashes by blocking a receptor called neurokinin B, which plays a role in the brain’s regulation of body temperature.

The FDA has placed its most serious warning - called a Boxed Warning - on the non-hormonal drug fezolinetant, which is sold under the brand name Veozah.

The FDA added a boxed warning to highlight known risk for rare but serious liver injury associated with the use of fezolinetant, a nonhormonal medication indicated for treating menopausal hot ...

The prescribing information for Veozah (fezolinetant) has been updated to include a boxed warning regarding the risk of hepatotoxicity, following the Food and Drug Administration’s review of a ...

Veozah (fezolinetant) was approved in 2023 by the FDA to treat moderate to severe hot flashes. A similar drug, elinzanetant, is currently under FDA review.